Similar Papers

Paper Title
Journal
Date
Author
Abstract P4-06-05: Treatment of ESR1 mutant and PIK3CA mutant patient-derived breast cancer xenograft models reveals differential anti-tumor responses to estrogen receptor degraders and PI3K inhibitors in vivo
A Young ... D Sampath
Cancer Research | VOL. 77
A Young, et. al.A Young ... D Sampath
14 Feb 2017
Patient-derived non-small cell lung cancer xenograft mirrors complex tumor heterogeneity.
Xuanming Chen ... Ke Chen
Cancer Biology and Medicine | VOL. 18
Xuanming Chen, et. al.Xuanming Chen ... Ke Chen
01 Jan 2020
Abstract A018: Patient-derived xenograft (PDX) models of NSCLC reflect clinical drug responses and predict effective treatments for patients
Daniel Ciznadija ... Igor Astaturov
Molecular Cancer Therapeutics | VOL. 17
Daniel Ciznadija, et. al.Daniel Ciznadija ... Igor Astaturov
01 Jan 2018
122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1
...
Annals of Oncology | VOL. 32
, et. al. ...
01 Dec 2021
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Table of Contents
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
Editorial Board
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study
E Rangelova ... Y Kimura
Annals of Oncology | VOL. -
E Rangelova, et. al.E Rangelova ... Y Kimura
01 Jan 2025
A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab, as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13 18 BEAT-meso trial
E Felip ... R Stahel
Annals of Oncology | VOL. -
E Felip, et. al.E Felip ... R Stahel
01 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.